| KMB |
Report |
Adjusted EPS attributable to K-C (Q2'26) |
MISS |
pred ~$1.82 vs. cons ~$1.87 (Q2'25 was $1.92; Q2 absorbs the ~$50M Mideast-inflation + LA DC-fire hit plus a ~26% adj. tax rate before 2H recovery) |
MEDIUM |
| KMB |
Report |
Organic sales growth (Q2'26) |
IN-LINE |
pred ~+1.9% vs. cons ~+2.3% (guided 'slightly below' Q1's +2.5% against the toughest comp of the year, +3.9%/+5% NA volume, plus ~$20M DC-fire drag) |
MEDIUM |
| KMB |
Report |
Net sales, continuing ops (Q2'26) |
IN-LINE |
pred ~$4.14B vs. cons ~$4.18B (roughly flat YoY vs $4.16B; ~-50bps private-label diaper exit, ~+50bps FX, DC-fire top-line hit) |
MEDIUM |
| KMB |
Guide |
FY2026 adj. EPS continuing ops growth |
UNCHANGED |
guide reaffirmed ~double-digit cc / ~$7.55 vs. cons ~$7.60 (FY2026); base case is a hold, not a raise |
MEDIUM |
| KMB |
Guide |
FY2026 adj. operating profit growth |
UNCHANGED |
guide ~mid-to-high single digit cc (~+6-8%) vs. cons ~+7% (FY2026); reaffirm is base case but real trim risk on 2H oil/input costs (mgmt cut in 2025 despite mitigation) |
LOW |
| KMB |
Guide |
FY2026 organic sales growth |
UNCHANGED |
guide ~in-line/ahead of category ~2.5% vs. cons ~2.4% (FY2026) |
MEDIUM |
| KMB |
Guide |
2H input-cost / oil overhang (not yet in guide) |
UNKNOWN |
guide ~$150-170M gross 2H inflation @ ~$100 oil vs. cons ~unquantified/$0 in-model (2H'26); whether they quantify + offset is the key swing |
LOW |
| KMB |
Guide |
Kenvue / FTC deal close timing |
UNCHANGED |
guide 2H 2026 close (FTC second request) vs. Street ~2H 2026; highest-beta commentary — any remedy/divestiture or slippage chatter would dominate |
MEDIUM |
| KMB |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| KMB |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
Stock ran ~+16% off the April low to a $114.72 early-July high before fading to $107.59, so the bar is elevated into a noisy, tough-comp print. Base case is a soft organic/EPS quarter (tax + ~$50M Q2 headwind) with the FY guide reaffirmed but a cautious, unquantified 2H oil/input-cost tone and no firm FTC catalyst. Out-period math (implicit 2H cost drag mgmt says will be 'recovered' but hasn't put in the guide) biases estimate revisions lower even on any headline in-line, so an initial negative reaction follows through rather than fades. Deal-spread/KVUE correlation (Beiersdorf's skincare cut is a negative read-through) adds downside; a clean guide reaffirm + on-track FTC could cap losses. |
LOW |